# Kollitab™ DC 87 L

Your new all-in-one tableting solution with filler, binder, disintegrant and lubricant.

How can Kollitab™ DC 87 L help you?

- Superior flowability
- High tablet strength at broad compression forces
- Fast disintegration



## **Key benefits**

# **Manufacturing**

- **Enables fast tablet development**
- Simplifies formulation development
- **Reduces manufacturing complexity**

# **Quality & Regulatory**

- ✓ Based on monographed excipients
- Provides advantages of all-in-one products (reduced Quality Control efforts, handling, and documentation)

	Kollitab™ DC 87 L	Ludipress®	Ludipress® LCE	Ludiflash®
Main use	Tablets	Tablets	Lozenges, Chewables, Effervescents	Orodispersables
Benefits	Lubricated all-in-one excipient for simplified direct compression.	Filler, binder and disintegrant for tablets, with flexibility to choose lubricant.	Filler and binder for reduced manufacturing steps.	Extremely fast disintegration with superior mouth feel.
Functionality	Filler, Binder, Disintegrant, Lubricant	Filler, Binder, Disintegrant	Filler, Binder	Filler, Binder, Disintegrant
Composition	Lactose monohydrate, Kollicoat® IR, Crospovidone, SSF*	Lactose monohydrate, Povidone, Crospovidone	Lactose monohydrate, Povidone	Mannitol, Polyvinyl acetate**, Crospovidone
Particle Size Distribution	•••	•	••	•
Flowability	•••	••	••	•
Tabletability	•••	••	••	•••
Compressibility	••	•	•	•••
Sensitivity to Overblending	Low	Depends on Lubricant	Depends on Lubricant	Depends on Lubricant













\*Sodium stearyl fumarate \*\*from Kollicoat® SR 30 D [Data from ZoomLab™ and internal lab testing]









#### Kollitab™ DC 87 L Technical Features

# **High Tablet Strength at Broad Compression Forces**



# **Fast Disintegration for High Strength Tablets**



#### Superior Flow vs. Blend of Individual Excipients


Lower cohesion implies better flowability.

Material	Flow Function	Cohesion (kPa)
Kollitab™ DC 87 L	37	0.17
Lactose Blend*	4	2.00

\*Lactose Blend: lactose monohydrate, crospovidone (Kollidon® CL F), copovidone (Kollidon® VA 64) and sodium stearyl fumarate

### **Well-designed Particle Shape**

Round particle shape leads to superior flowability.



# Predict your next drug's starting formulation instantly

Start with an active ingredient, define your target profile, input your preferences, and let the advanced algorithm optimize your formulation.

Leverage ZoomLab™ to accelerate formulation and time-to-market.

#### **Your Virtual Quality & Regulatory Assistant**

Use RegXcellence® to simplify the compliance process. Instantly access documentation & more!



Sign-up today at: https://info-mypharma.basf.com

#### Contact us at pharma-solutions@basf.com

good faith and is believed to be accurate as of the date of issuance. Unless expressly agreed otherwise in writing in a supply contract or other written agreement between you and BASF

- (a) To the fullest extent not prohibited by the applicable laws, BASF EXPRESSLY DISCLAIMS ALL OTHER REPRESENTATIONS, WARRANTIES, CONDITIONS OR GUARANTEES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, WRITTEN OR ORAL, BY FACT OR LAW, INCLUDING ANY IMPLIED WARRANTIES, REPRESENTATIONS OR CONDITIONS OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, SATISFACTORY QUALITY, NON-INFRINGEMENT, AND ANY REPRESENTATIONS, WARRANTIES, CONDITIONS OR GUARANTEES, ARISING FROM STATUTE, COURSE OF DEALING OR USAGE OF TRADE and BASF HEREBY EXPRESSLY EXCLUDES AND DISCLAIMS ANY LIABILITY RESULTING FROM OR IN CONNECTION WITH THIS DOCUMENT OR ANY INFORMATION PROVIDED HEREIN, including, without limitation, any liability for any direct, consequential, special, or punitive damages relating to or arising therefrom, except in cases of (i) death or personal injury to the extent caused by BASF's sole negligence, (ii) BASF's willful misconduct, fraud or fraudulent misrepresentation or (iii) any matter in respect of which it would be unlawful for BASF to exclude or restrict liability under the applicable laws:
- (b) Any information provided herein can be changed at BASF's sole discretion anytime and neither this document nor the information provided herein may be relied upon to satisfy from any and all obligations you may have to undertake your own inspections and
- (c) BASF rejects any obligation to, and will not, automatically update this document and any information provided herein, unless equired by applicable law; and
- (d) The user is responsible for confirming that the user has retrieved the most current version of this document from BASF as



BASF\_Pharma in BASF Pharma Solutions

www.pharma.basf.com

This document, or any information provided herein does not constitute a legally binding obligation of BASF and has been prepared in **Inspiring Medicines for Better Lives**